Friends and Foes: Our Evolving Understanding of the Link Between Fbxw7 and P53 in Cancer

Overview

Journal Neoplasia

Publisher Elsevier

Specialty Oncology

Date 2020 Oct 19

PMID 33070871

Citations 2

Authors

C Elizabeth Caldon

Affiliations

Soon will be listed here.

Citing Articles

FBXW7 and human tumors: mechanisms of drug resistance and potential therapeutic strategies.

Wang W, Jiang K, Liu X, Li J, Zhou W, Wang C Front Pharmacol. 2023; 14:1278056.

PMID: 38027013 PMC: 10680170. DOI: 10.3389/fphar.2023.1278056.

Clinical significance of FBXW7 loss of function in human cancers.

Fan J, Bellon M, Ju M, Zhao L, Wei M, Fu L Mol Cancer. 2022; 21(1):87.

PMID: 35346215 PMC: 8962602. DOI: 10.1186/s12943-022-01548-2.

References

Tripathi V, Kaur E, Kharat S, Hussain M, Damodaran A, Kulshrestha S . Abrogation of FBW7α-dependent p53 degradation enhances p53's function as a tumor suppressor. J Biol Chem. 2019; 294(36):13224-13232. PMC: 6737220. DOI: 10.1074/jbc.AC119.008483. View

Musgrove E, Sutherland R . Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer. 2009; 9(9):631-43. DOI: 10.1038/nrc2713. View

Cui D, Xiong X, Shu J, Dai X, Sun Y, Zhao Y . FBXW7 Confers Radiation Survival by Targeting p53 for Degradation. Cell Rep. 2020; 30(2):497-509.e4. DOI: 10.1016/j.celrep.2019.12.032. View

Galindo-Moreno M, Giraldez S, Limon-Mortes M, Belmonte-Fernandez A, Reed S, Saez C . SCF(FBXW7)-mediated degradation of p53 promotes cell recovery after UV-induced DNA damage. FASEB J. 2019; 33(10):11420-11430. PMC: 6766643. DOI: 10.1096/fj.201900885R. View

Kitade S, Onoyama I, Kobayashi H, Yagi H, Yoshida S, Kato M . FBXW7 is involved in the acquisition of the malignant phenotype in epithelial ovarian tumors. Cancer Sci. 2016; 107(10):1399-1405. PMC: 5084658. DOI: 10.1111/cas.13026. View

Yokobori T, Mimori K, Iwatsuki M, Ishii H, Onoyama I, Fukagawa T . p53-Altered FBXW7 expression determines poor prognosis in gastric cancer cases. Cancer Res. 2009; 69(9):3788-94. DOI: 10.1158/0008-5472.CAN-08-2846. View

Meyer A, Furumo Q, Stelloh C, Minella A, Rao S . Loss of Fbxw7 triggers mammary tumorigenesis associated with E2F/c-Myc activation and Trp53 mutation. Neoplasia. 2020; 22(11):644-658. PMC: 7573506. DOI: 10.1016/j.neo.2020.07.001. View

Cuevas I, Sahoo S, Kumar A, Zhang H, Westcott J, Aguilar M . Fbxw7 is a driver of uterine carcinosarcoma by promoting epithelial-mesenchymal transition. Proc Natl Acad Sci U S A. 2019; 116(51):25880-25890. PMC: 6926017. DOI: 10.1073/pnas.1911310116. View

Grim J, Knoblaugh S, Guthrie K, Hagar A, Swanger J, Hespelt J . Fbw7 and p53 cooperatively suppress advanced and chromosomally unstable intestinal cancer. Mol Cell Biol. 2012; 32(11):2160-7. PMC: 3372235. DOI: 10.1128/MCB.00305-12. View

10.

Yeh C, Bellon M, Nicot C . FBXW7: a critical tumor suppressor of human cancers. Mol Cancer. 2018; 17(1):115. PMC: 6081812. DOI: 10.1186/s12943-018-0857-2. View

11.

Minella A, Grim J, Welcker M, Clurman B . p53 and SCFFbw7 cooperatively restrain cyclin E-associated genome instability. Oncogene. 2007; 26(48):6948-53. DOI: 10.1038/sj.onc.1210518. View

12.

Wang Z, Inuzuka H, Zhong J, Wan L, Fukushima H, Sarkar F . Tumor suppressor functions of FBW7 in cancer development and progression. FEBS Lett. 2012; 586(10):1409-18. PMC: 3372850. DOI: 10.1016/j.febslet.2012.03.017. View

13.

Minella A, Loeb K, Knecht A, Welcker M, Varnum-Finney B, Bernstein I . Cyclin E phosphorylation regulates cell proliferation in hematopoietic and epithelial lineages in vivo. Genes Dev. 2008; 22(12):1677-89. PMC: 2428064. DOI: 10.1101/gad.1650208. View